© 2021 BioMarin. All rights reserved.

Back to Leadership

Lon Cardon, Ph.D., FMedSci, joined BioMarin in September 2017 and currently serves as Chief Scientific Strategy Officer, Senior Vice President, a role that aims to enrich BioMarin’s pipeline, which drives the company’s future growth.

From 2017 to October 2019, Dr. Cardon served as BioMarin’s Chief Scientific Officer, with the aim to further advance the translation of genetic discoveries to new treatments for both common and rare disorders. Prior to joining BioMarin, Dr. Cardon was a Senior Vice President at GlaxoSmithKline, leading a number of platform groups spanning Genetics, Molecular Biology, Computational Biology, Statistics, Epidemiology and Clinical Pharmacokinetics, and later a pipeline division called Alternative Discovery and Development. He has also been a senior academic in the U.K. and U.S., serving as Professor of Bioinformatics at the University of Oxford and Professor of Biostatistics at the University of Washington and Fred Hutchinson Cancer Research Center.

He received his Ph.D. from the Institute for Behavioral Genetics at the University of Colorado and conducted his postdoctoral research in the Department of Mathematics at Stanford University. He has been awarded a Wellcome Trust Principal Fellowship and is an elected Fellow of the U.K.’s Academy of Medical Sciences and the American Association for the Advancement of Science.

Dr. Cardon has authored more than 225 scientific publications and 15 books and chapters, mainly focused on statistical genetics methodology and applications for many rare and common diseases, ranging from Huntington’s disease to dyslexia. In addition, he currently serves as Co-Chair of the Genomics Working Group on the National Institute of Health’s All of Us Research Program Advisory Panel. The panel provides strategic counsel on the program’s historic effort to gather data from one million or more people living in the United States to accelerate research and improve health.


Our Pipeline

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

View Now Our Pipeline